US FDA Wades Into Reimbursement Issues With Upcoming Stakeholder Meeting On Alzheimer’s Drug Coverage, Evidence Challenges

Convened by the Duke-Margolis Health Policy Center, the meeting later this month will not be open to the public. But the center expects to continue to engage with stakeholders on the issues in the coming weeks and months.

Discussions Will Focus On Monoclonal Antibody Drugs For Alzheimer's • Source: Alamy

More from Real-World Evidence

More from Clinical Trials